Pluri (PLUR) Asset Writedowns and Impairment (2017)
Pluri (PLUR) reported Asset Writedowns and Impairment of $850000.0 for Q3 2017.
Pluri (PLUR) Asset Writedowns and Impairment (2017) Analysis & Trends
Pluri (PLUR) has 1 years of Asset Writedowns and Impairment data on file, last reported at $850000.0 in Q3 2017.
- Asset Writedowns and Impairment for Q3 2017 came in at $850000.0, changed N/A year-over-year; the trailing twelve-month figure through Jun 2018 was $850000.0 (changed N/A YoY), and the FY2018 annual result was $850000.0, up 10.82% from the prior year.
- Asset Writedowns and Impairment was little changed at $850000.0 in Q3 2017 per PLUR's latest filing.
- Over five years, Asset Writedowns and Impairment peaked at $850000.0 in Q3 2017 and troughed at $850000.0 in Q3 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Pluri | 21.39 Mn | 21.87 Mn | 86,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 850,000.00 |
| Sep 30, 2017 | 850,000.00 |